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Abstract 
Current practice in economic evaluation is to assign equal social value to a unit of 
health improvement (“a QALY is a QALY is a QALY”). Alternative views of equity 
are typically considered separately to efficiency. One proposal seeks to integrate these 
two sets of societal concerns by attaching equity weights to QALYs. To date, research 
in pursuit of this goal has focussed on candidate equity criteria and methods for 
estimating such weights. It has implicitly been assumed that should legitimate, valid, 
and reliable equity weights become available, it would be a straightforward task to 
incorporate them into as a separate simple calculation after estimating cost per un-
weighted QALY. This paper suggests that in many situations these simple approaches 
to incorporating equity weights will not appropriately reflect the preferences on which 
the weights are based and therefore equity weights must be incorporated directly into 
the cost effectiveness analysis. In addition, to these technical issues, there are a 
number of practical challenges that arise from the movement from implicit to explicit 
consideration of equity. Equity weights should be incorporated in economic 
evaluation, but not until these challenges have been appropriately addressed. 
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1. Introduction 
Against a backdrop of rising healthcare costs, decision makers the world over 
increasingly consider issues relating to the economic efficiency of alternative uses of 
limited healthcare budgets. The last two decades in particular have seen a shift away 
from decision making which traditionally considered only issues relating to safety and 
efficacy, to processes which also incorporate consideration of cost effectiveness. As 
the role of economic evaluation in decision making has become more prominent, 
there have been parallel developments in the methods for conducting such studies 
(Drummond and McGuire, 2001).  
 
One field in particular that has witnessed substantial methodological development is 
that of the measurement and valuation of health outcomes. This, in turn, has resulted 
in measures such as the Quality Adjusted Life Year (QALY) establishing a dominant 
position as the outcome measure for economic evaluations in many jurisdictions. 
However, whilst the use of QALYs in cost effectiveness analysis (CEA) is compatible 
with the aim of maximising health benefits, this is unlikely to be the sole goal either 
of health care decision makers (Drummond and McGuire, 2001; PHARMAC; NICE, 
2007) or of the populations they serve (Schwappach, 2002; Dolan et al., 2005). The 
implicit equity approach embodied in CEA is to assign equal value to each unit of 
health gain, irrespective of the characteristics of the recipients, how the benefit is 
generated, or the reason an intervention is required in the first place (“a QALY is a 
QALY is a QALY”). This approach has long been questioned (see Dolan et al., 2006 
for a review), yet no formal framework exists which would permit alternative 
approaches to equity to be incorporated. In the absence of a formal approach, decision 
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makers must rely on implicit trade-offs between competing equity and efficiency 
criteria, or may even consider certain equity criteria as rights which trump all 
consequential issues, including cost effectiveness. In the former case, the criteria by 
which decisions are reached cannot be entirely transparent and there is a strong risk of 
inconsistency across decisions; in the latter case, opportunity cost is not considered 
and therefore economic evaluation becomes redundant. 
 
An alternative approach to this implicit incorporation of equity has been proposed 
whereby societal preferences across different equity criteria would be used to 
construct values for adjusting QALYs. These so called “equity weights” would be 
used to generate estimates of cost per equity adjusted QALY and decisions based on 
this figure and willingness to pay per “super” QALY (Wagstaff, 1994; Williams, 
1997; Nord et al., 1999; Dolan and Olsen, 1999; Dolan and Tsuchiya, 2006). A larger 
proportion of the information relevant to decision makers would be brought inside the 
analytical framework of cost effectiveness by the development of this maximand 
(Dowie, 1998).  
 
It is worth noting that there may also be efficiency based reasons for proposing that 
some characteristics attract a greater weight than others. For example, it could be 
argued that the desire to allocate greater weight to parents rather than non parents is 
motivated by efficiency rather than equity concerns. Disaggregating these motives, 
particularly in relation to age weights, may be an important task. The discussion 
below refers to equity weights but the same considerations will apply to efficiency 
weights as well. 
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The equity weighted QALY approach may be appealing to some but has not been 
considered viable to date due to uncertainties about relevant equity characteristics, 
insufficient data and a lack of agreement on methods with which to estimate the 
required weights. However, beneath these concerns, it has been implicitly assumed 
that should legitimate, valid and reliable weights become available, it would be 
relatively straightforward to incorporate those weights into CEA.  
 
This paper argues that in order to avoid misrepresenting the preferences over health 
outcomes and equity that the use of QALYs in conjunction with equity weights is 
intended to reflect, more complex methods will often be required. The appropriate 
application of equity weights is challenging and remaining technical, methodological 
and evidential challenges require consideration before equity weights can be explicitly 
incorporated into health care decision making. Candidate equity characteristics may 
include age, gender, severity of the untreated condition and accountability for ill 
health, and we will use some of these in our hypothetical examples in this paper.  
However, it is not our objective to argue for (or against) any of these characteristics 
per se in this paper. 
 
2. Challenges to incorporating equity weights into cost effectiveness analyses 
 
In considering the importance of some of the potential challenges to using equity 
weights, it is important to recognise that the aim is to reflect public preferences over 
the distribution of health outcomes. “Equity” in this approach operates at the same 
level as QALY maximisation, that is, in making decisions between and within broad 
groups of patients and not at the individual patient level. Two general types of 
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concerns to using equity weights are identified in relation to the aim of improving 
decision making at this level. First, there are technical challenges to accurately 
reflecting preferences over efficiency and equity. Second, moving away from a 
decision making framework in which equity is considered in terms that are not 
commensurable with those used to express efficiency, to an approach in which equity 
is implicit to the analysis gives rise to a number of potentially problematic issues.    
 
2.1 Simple incorporation of equity weights into CEA 
There are two straightforward approaches to incorporating equity weights alongside 
cost per QALY calculations. In both cases, this occurs as a separate stage to the 
calculation of the costs and un-weighted QALYs for the interventions under 
considerations.  
  
The first approach adjusts the number of additional QALYs generated by an 
intervention according to the relevant equity weight and compares this to the standard 
willingness to pay threshold. For example, an intervention generating 5 additional 
QALYs in a patient group for whom an equity weight of 1.5 was considered 
applicable would generate 7.5 equity weighted QALYs. Provided the additional cost 
was no more than £150,000 then this would be considered a cost effective 
intervention, assuming a threshold of £20,000 (£150,000 / 7.5QALYs). 
 
The alternative approach adjusts the willingness to pay threshold used to determine 
whether an intervention is cost effective. Since the threshold incremental cost 
effectiveness ratio (ICER) is the inverse of the marginal health gain per unit of 
expenditure of the displaced intervention, this approach in effect downgrades the 
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QALYs for the displaced group based on the equity weight applicable to the 
recipients of the new intervention. For example, imagine an intervention which 
generates 5 additional QALYs at an additional cost of £125,000. The ICER of 
£25,000 would be judged against an equity weighted threshold value. If the usual 
threshold of £20,000 were adjusted to take into account the equity weight of 1.5, this 
results in an equity weighted threshold of £30,000 and the new intervention would be 
considered cost effective. Implicitly, the QALYs generated by those that bear the 
opportunity cost have been factored down by the equity weight.  
 
Whilst these two approaches are mathematically equivalent, the second approach of 
adjusting the threshold highlights an apparent inconsistency. The QALYs generated in 
one group of patients are adjusted not according to the characteristics of the patients 
that receive those health benefits, but according to the characteristics of a different 
patient group. This issue is discussed in more detail below.    
  
2.2 Technical challenges 
In many situations, the time horizon over which cost and benefit differences between 
treatment options accrue is long term. Therefore, for many interventions for chronic 
conditions, it is appropriate to use decision models to make what can be life long 
estimates. However, it is also likely that relevant equity characteristics will change 
over time for the patients considered in these models. Of the likely candidate criteria 
for equity weights, this is most obvious in relation to age but is also important to other 
characteristics. For example, characteristics such as individual responsibility for ill 
health may take a complex pattern over time depending on whether or not patients 
continue with the health damaging behaviour beyond disease onset or where risk 
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taking behaviour is related to life stage characteristics such as having children. In 
these situations, where not only do the patient characteristics attracting equity weights 
and the size of these weights change over the relevant time frame of the model, but 
they also may have an impact on clinical effectiveness, the application of a constant 
equity weight (as implied by adjusting either the final QALYs generated and thereby 
the final ICER, or the threshold willingness to pay) will not be appropriate. The 
calculation of cost effectiveness will need to recognise that over time, as patients 
progress through a model, they may attract differing weights.    
 
Whilst this raises the need to incorporate equity weights directly into the modelling 
process, it also raises an important issue regarding the status and interpretation of age 
based weights. Attaching different weights according to patient age as they progress 
through a model is assumed to reflect the preferences of the general population from 
whom equity weights will be elicited, but this is only the case if these weights reflect 
true preferences for age rather than a cohort effect. For example, it has been suggested 
that equity weights could reflect preferences towards the current very elderly cohort 
due to the payment of national insurance contributions over a lifetime and the implicit 
contracts with the state that many thought this entailed (Johnson and Falkingham, 
1992). This may not be considered relevant to younger cohorts when they reach the 
same age given that the link between contributions and entitlements is no longer 
explicit. The precise way in which changing equity weights should be used to reflect 
changing patient age within models will require a detailed understanding of the 
reasons why such preferences exist in order to appropriately reflect those preferences. 
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In addition, it is unlikely that any group of patients will be homogenous with respect 
to the equity characteristics of relevance, including those that change over the 
appropriate time horizon. Thus, within a patient group, some patients’ health gains 
will be valued more highly than others for equity reasons, even when the size of the 
health gain is the same. In this situation, two approaches are feasible. The first is to 
define patient subgroups according to equity characteristics as well as the more 
traditionally accepted subgroups defined in terms of characteristics that affect clinical 
outcomes or cost. The second is to estimate the true equity weighted ICER for a 
patient group that is a weighted average of the patients it contains. The two 
approaches may lead to very different conclusions and challenges. The first approach 
gives rise to the possibility of decision makers being faced with an ordering of 
treatment options by group that may conflict with the ordering of health benefits (or 
even the costs) derived by those groups. This will occur where characteristics which 
attract equity weights are negatively correlated with effectiveness and the former 
outweigh the latter. This may give rise to significant challenges for decision makers. 
Yet the second approach which would obscure such decisions, in fact entails the 
inconsistency of being prepared to use the valuations of the general population in one 
element of the decision (the incorporation of the equity weights) yet ignores them at 
the subsequent stage. This inconsistency would penalise certain groups: either those 
for whom the proposed treatment is cost effective but are denied because the decision 
groups them with other “worse” patient groups, or those who bear the opportunity 
cost of positive decisions that give treatment to those in whom the intervention is only 
cost effective because they have been grouped with a “better” equity group. The 
incorporation of equity weights at the analytical stage of the decision making process 
requires they are considered legitimate (in terms of acceptability of differentiating 
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between patients in terms of the particular characteristics and in terms of the 
robustness of the estimates). A consistent approach would also apply these weights at 
the decision making stage. 
 
The simplistic approaches to incorporating equity weights will be sufficient when the 
patients under consideration are homogenous with respect to these equity 
characteristics. Whilst it is rarely the case that interventions are relevant only to 
patients of a particular age, we must also consider the degree to which equity weights 
themselves distinguish groups in order to determine how frequently a simplistic 
approach will be sufficient in practice. Where equity weights are quite ‘lumpy’, for 
example, in the case of age, only distinguishing between children, adults and the 
elderly, then the simplistic approaches may be appropriate more frequently. However, 
this may be expected to diminish over time as the evidence base on which equity 
weights are founded is developed.  
 
This task may be further complicated by the fact that equity preferences are likely to 
exist over several characteristics. The appropriate weight to be applied to any 
individual patient or group of patients will not solely be a function of their status in 
each equity domain but will be determined by the interaction between these domains. 
To estimate the form of the equity weight function requires an evidence base that does 
not currently exist. Without knowing whether applying numerous equity weights 
should be done in multiplicative, additive or another form risks introducing a bias that 
may be no more defensible than the use of un-weighted QALYs that the weights were 
intended to replace. Indeed, there is currently no agreement as to the equity domains 
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that that should be considered legitimate: a task that clearly must precede the 
challenge of identifying the appropriate functional form for multiple characteristics. 
 
 
 
2.3 Implicit versus explicit equity positions 
Moves towards the explicit incorporation of equity weights into cost effectiveness 
analysis must recognise that current practice is not free of equity implications and, to 
avoid the risk of double counting, their impact must be factored out.  
 
For example, in the hypothetical case where equity weights for social class attach 
greater importance to health gains generated by those in the lower compared to the 
higher classes, it would be important to factor out any difference in health gain due to 
differential life expectancy. For a life saving intervention, current practice would not 
estimate ICERs for subgroups defined by class even though these could differ 
substantially: life expectancy at birth is approximately 7 years more for professionals 
compared to unskilled manual workers in the United Kingdom (Office for National 
Statistics, 2008). At the margin, the implicit equity approach embodied in current 
practice could lead to therapies being provided to populations in whom they are not 
cost effective, and not provided in populations in whom they are cost effective. If 
explicit equity weights are to be incorporated into cost effectiveness analyses these 
implicit weights ought first to be removed, that is, the health course with and without 
the experimental treatment and the costs incurred in all states within the health course 
should all be equity sub-group specific. Only then should explicit equity weights be 
introduced in order to avoid double counting.   
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Current practice would need to be amended where any of the characteristics which 
attract equity weights are also related to any factor that influences either expected 
benefits or costs. Examples are life expectancy, compliance with treatment and 
vulnerability to complications. Whilst this has implications for the generation of data 
which could inform these equity weighted subgroup estimates, there may also be 
other unintended consequences. Compared to current approaches that do not 
distinguish such groups, the estimation of equity based subgroups might actually 
disadvantage those in the groups equity weights are intended to favour. This will 
occur where the true estimates of effectiveness (lower life expectancy for lower social 
classes in the above example) are not offset by the additional equity weighting of 
those benefits. 
 
One may think that such an outcome is unacceptable and that the introduction of 
equity weights should always advantage the vulnerable group.   However, the 
dilemma arises because current practice masks the fact that benefits are inflated in a 
way that becomes difficult to defend once explicit weights are derived. 
 
Finally, it must be recognised that economic evaluation is founded on the principle of 
opportunity cost and care must be taken if equity weights are to be applied only to the 
denominator in cost per QALY analyses. In the case of decision making within a 
limited health care budget, the additional costs associated with any intervention 
represent foregone health benefits by other patients. If no explicit consideration is 
given to the equity characteristics of patients that bear the opportunity cost then the 
implied assumption is that these foregone benefits are equity neutral, that is they are 
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assigned a unitary weight.  Whilst it may be difficult to predict where the opportunity 
cost will fall, and this will differ according to the decision making environment and 
the technologies in question, it should not automatically be assumed that the losers 
will be equity neutral. It has been suggested that the opportunity cost tends to fall on 
patient groups that lack a high  profile with the general public or enjoy powerful 
clinical support, even where these are within the same specialty (Barrett et al., 2006) – 
precisely the groups of patients that are likely to attract strong equity weights. 
 
In fact, equity weights must be neutral across the population to which the health care 
budget is applied. Therefore, the incorporation of weights into decision analysis must 
be prepared to apply weights which downgrade the health benefits in some 
populations as well as upgrade them in others. If analyses routinely apply weights of 
one or greater to the populations that are the subject of decisions based on economic 
evaluations, then the implication is not that the populations that bear the opportunity 
cost are equity neutral but that they are in fact equity negative. The question for 
analysts and decision makers in every analysis should be “which” weight to apply, 
which is determined both by the recipients of the intervention under consideration and 
those likely to bear the opportunity cost, not whether a weight should be applied at all. 
 
3. Conclusions 
In this paper we have attempted to describe why the incorporation of equity weights 
into cost effectiveness analysis will often be more complicated than has previously 
been considered. The simplistic approaches of either adjusting the willingness to pay 
threshold or the final ICER will be liable to misrepresentations of public preferences. 
Approaches which factor equity weights directly into the estimation of costs and 
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benefits should therefore be favoured. We recognise that this may impose a further 
degree of complication to an area that has seen rapid ratcheting up of analytical 
techniques over the past decade (for example by increasingly complex model types 
and analysis of uncertainty). Indeed, there may be an increasingly frequent need for 
more complex individual sampling models to truly represent equity weights because 
of the need to incorporate patient history. This in turn may conflict with other 
techniques such as the ability to perform probabilistic sensitivity analysis. Thus, the 
move to the incorporation of equity weights into decision making may have broader 
methodological research implications.  
 
This is not to argue that we should avoid taking explicit account of society’s 
preferences over equity. We broadly agree with the arguments by Cookson and 
Williams (2000) for transparency in decision making processes.  The development of 
decision making processes is dynamic. At any point in time, there are arguments in a 
decision problem that cannot be adequately captured in the analytical processes that 
inform decision making. This may be due to lack of evidence or the absence of an 
adequate analytical technique. It is part of the decision maker’s role to take account of 
these arguments as well as the analytical evidence that does exist in order to arrive at 
a decision.  Over time, in the interests of transparency and consistency, decision 
making processes should aspire to increase the proportion of arguments in the 
decision problem that are addressed analytically and reduce the degree to which the 
decision is determined in the ‘black box’ of the decision maker’s head.  It is important 
to understand that acknowledging that some important issues in a decision cannot be 
addressed analytically is not an argument for reverting to simplistic cost consequence 
type analyses. 
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There are therefore clear challenges yet to be addressed by different groups. At the 
political level, there must be direction given as to which of the potential equity 
characteristics may be considered legitimate, with the potential for health care 
resources to be directed differentially between these groups. At the methodological 
level, there remains the challenge of estimating reliable weights and the appropriate 
functional form for combining them together. For cost effectiveness analysts and the 
recipients of those analyses there will be challenges in incorporating weights in a 
manner that respects societal preferences over efficiency and equity and in 
recognising the appropriate weights to apply to different groups.  
 
To conclude, whilst the aim of incorporating equity weights into cost effectiveness 
analyses should be pursued, it must be recognised that this will not be straightforward. 
There has been some expectation that the most difficult stage in this endeavour is in 
establishing legitimate, valid and reliable weights, and that once these are available it 
would be a relatively simple calculation to apply them to the analyses. This paper has 
pointed out that there are further remaining challenges on the way. Equity weights 
should be incorporated in economic evaluation, but not until these challenges have 
been appropriately addressed. 
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